Evidence map›Paper›PMID 42504115›Full record

ArticleJournal of immunology research2026

MX2 and IRF7 are Associated With Disease Activity and Renal Involvement in Systemic Lupus Erythematosus: An Exploratory Study.

FengQi Zhang, YiChen Huang, Hang Liu, YiYang Zhang, ZhiYu Li, ZhiJun Xie, Jing Sun

Abstract read
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

FengQi ZhangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, zcmu.edu.cn.
YiChen HuangDepartment of Internal Medicine, Yuyao Hospital of Traditional Chinese Medicine, Yuyao, Zhejiang, China.
Hang LiuSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, zcmu.edu.cn.
YiYang ZhangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, zcmu.edu.cn.
ZhiYu LiThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China, zjhtcm.com.ORCID https://orcid.org/0000-0002-7320-8983
ZhiJun XieSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, zcmu.edu.cn.ORCID https://orcid.org/0000-0002-9268-4029
Jing SunThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China, zcmu.edu.cn.ORCID https://orcid.org/0000-0002-2585-9618

Funding

2024 Zhejiang Chinese Medicine University Cultivation Plan for Top Innovative Talents of Postgraduates 2024YJSBJ005Key Research and Development Program of Zhejiang Province 2024C03191National Natural Science Foundation of China 82374395National Natural Science Foundation of China 82405084Zhejiang Provincial Science and Technology Program of Traditional Chinese Medicine 2024ZR016
6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) has multiple phenotypes, one of which is lupus nephritis (LN), a very serious complication with a high mortality rate. Patients with LN may require different treatment regimens than patients with SLE, as there are significant differences between SLE and LN pathogenesis; however, to date, no biomarkers specific for LN have been characterized. Identification of immunological markers of LN could therefore facilitate more individualized treatment strategies. MATERIALS AND

methodsUsing public datasets (GSE121239), we screened patients based on SELENA-SLEDAI scores into mild (SLELA), moderate-to-severe (SLEHA), and healthy control (HC) groups. Bioinformatics analyses identified differentially expressed genes (DEGs), which were analyzed for functional pathway enrichment and immune cell infiltration. We validated these findings in an independent clinical cohort of 40 SLE patients (20 with LN and 20 without LN) and 20 HC individuals. LN diagnosis was confirmed by renal biopsy or clinical criteria. We assessed disease activity using clinical indicators and measured the expression of MX2, IRF7, and TRIM69 in peripheral blood mononuclear cells (PBMCs) via real-time quantitative PCR (n = 40). Serum interferon-α (IFN-α) levels were measured by ELISA, and protein expression in kidney tissue was detected by immunofluorescence (IF).

resultsWe observed differential expression of 32 disease activity-related genes in SLE. Univariate logistic regression and ROC curve analysis indicated that MX2 (AUC = 0.95, 95% CI: 0.92-0.98), TRIM69 (AUC = 0.93, 95% CI: 0.89-0.96), and IRF7 (AUC = 0.91, 95% CI: 0.87-0.95) were associated with SLE diagnosis. Gene ontology functional enrichment analysis suggested that the type I IFN pathway is aberrantly activated in SLE. Disease activity-related genes such as MX2, IRF7, and IFIT3 are functionally enriched in the type I IFN pathway, and abnormal infiltration of neutrophils is involved in SLE pathogenesis. Disease activity-related genes such as MX2 and IRF7 were positively correlated with immune cell infiltration, including neutrophils and memory B cells. RT-qPCR and ELISA showed significantly higher expression of IFN-α, MX2, and IRF7 in LN patients than in SLE patients. IF assays showed that IFN-α, MX2, and IRF7 were expressed at significantly higher levels in the kidneys of LN patients than in SLE patients.

conclusionsOur study identifies MX2 and IRF7 as candidate biomarkers associated with high systemic disease activity in SLE. In our validation cohort, their expression was significantly elevated in patients with LN, suggesting they may serve as potential noninvasive indicators warranting further longitudinal investigation for LN risk assessment.

Indexed as

Interferon Regulatory Factor-7KidneyLupus Erythematosus, SystemicLupus NephritisMyxovirus Resistance ProteinsAdultBiomarkersComputational BiologyFemaleGene Expression ProfilingHumansInterferon-alphaLeukocytes, MononuclearMaleMiddle AgedSeverity of Illness IndexBiomarkersInterferon-alphaInterferon Regulatory Factor-7IRF7 protein, humanMyxovirus Resistance Proteinsbioinformatics analysismachine learningSLEDAIsystemic lupus erythematosustype I interferon

Identifiers

PMID42504115
PMCPMC13402894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.